This trial is evaluating whether Inclisiran sodium 300 mg will improve 1 primary outcome and 3 secondary outcomes in patients with Atherogenesis. Measurement will happen over the course of From randomization to total follow-up time (up to 72 months).
This trial requires 15000 total participants across 2 different treatment groups
This trial involves 2 different treatments. Inclisiran Sodium 300 Mg is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Current treatments for atherogenesis are highly dependent on the atherosclerotic burden of the patient. For example, current treatment of plaque stabilization is targeted primarily at symptomatic patients with high burden, while treatment for complete occlusion usually includes arterial bypass for symptomatic patients with low burden." - Anonymous Online Contributor
"About 15% of the American population has atherogenesis a year. However, in both whites and blacks, the mean age at initiation of the disorder is similar across all age groups." - Anonymous Online Contributor
"Atherogenesis involves fatty growths on the walls of the blood vessels. Normally, atherogenesis occurs after the accumulation of LDL (low density lipoprotein). A person is more likely to get an acute coronary event (heart attack or stroke) if, over a period of many years, the LDL is high, and HDL (high-density lipoprotein) is low. In some types of coronary artery disease, atherogenesis arises within the walls of arteries already rich in cholesterol—so-called vulnerable arteries, characterized by narrow and stiffening muscular walls and reduced blood flow of the vessels." - Anonymous Online Contributor
"The current therapies are effective in reducing cardiovascular risk factors and mortality in patients with atherosclerotic disease. Although there is evidence for a reduced risk of stroke and mortality from subcutaneous fatty degeneration in statin treated patients, the current evidence is not strong enough to definitively recommend therapy for subcutaneous fatty degeneration." - Anonymous Online Contributor
"Many diseases are associated with premature death due to atherogenesis but what initiates the disease process remains a mystery. Theories to study this question include an increased inflammatory response or an increased susceptibility to injury. It is likely, however, that a combination of factors causes the premature death." - Anonymous Online Contributor
"The most common signs of atherogenesis include an increased low density lipoprotein cholesterol level, triglyceride level, and pulse pressure. Atherogenesis can also result in the development of a plaque on the artery wall." - Anonymous Online Contributor
"Data from a recent study reported here are the strongest evidence that CVD phenotypes in populations have some heritability, although they may be in part explained (or at least not explained entirely by) environmental components and their modifiers." - Anonymous Online Contributor
"We used the doses of inhisiran sodium 300 mg in this study for the treatment of advanced prostate cancer. A statistically significant higher rate of PSA-independent tumour-free survival can be obtained if inhisiran sodium 300 mg is administered in combination with chemotherapy." - Anonymous Online Contributor
"In contrast to a 100 mg oral sodium load, a 300 mg oral sodium load did not significantly alter arterial wall thickness nor the level of oxidative stress. Whether these results translate into a longer duration of action of INGL-300 needs to be established in longitudinal studies." - Anonymous Online Contributor
"Inclisiran sodium 300 mg is not superior to placebo in a secondary prevention study in patients with atherosclerotic cardiovascular disease (AVD). Inclisiran sodium 300 mg should not be utilized for use in secondary prevention in patients with AVD." - Anonymous Online Contributor
"The study showed that, regardless of the medication prescribed to patients who received inclisiran 300 mg daily, the decline in the cognitive function of patients with diabetic nephropathy is relatively stable. These patients with diabetic nephropathy can be treated with this medication with no significant additional risk. However, further work is needed to understand how inclisiran affects the decline of the cognitive function of patients with diabetic nephropathy, before initiating a clinical trial." - Anonymous Online Contributor
"The most common side effects are: hypertension, headache, nausea, and dizziness. Symptoms disappear after the drug is administered and if left untreated, they may occur again after the treatment is stopped. There have been no deaths as of yet during treatment." - Anonymous Online Contributor